BioDelivery Sciences International Inc. (NASDAQ:BDSI) – Equities researchers at Roth Capital cut their Q2 2017 earnings estimates for BioDelivery Sciences International in a report issued on Monday. Roth Capital analyst S. Henry now forecasts that the firm will earn ($0.19) per share for the quarter, down from their previous estimate of ($0.18). Roth Capital currently has a “Buy” rating and a $7.00 target price on the stock.

BioDelivery Sciences International (NASDAQ:BDSI) last announced its quarterly earnings results on Wednesday, November 9th. The specialty pharmaceutical company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.04. BioDelivery Sciences International had a negative net margin of 93.61% and a negative return on equity of 309.49%. The firm earned $3.60 million during the quarter, compared to analysts’ expectations of $3.58 million. During the same quarter in the prior year, the business earned ($0.39) EPS. The company’s quarterly revenue was up 200.0% compared to the same quarter last year.

Earnings History and Estimates for BioDelivery Sciences International (NASDAQ:BDSI)

Several other brokerages have also weighed in on BDSI. Janney Montgomery Scott upgraded BioDelivery Sciences International from a “neutral” rating to a “buy” rating and upped their price objective for the company from $2.45 to $4.00 in a report on Friday, September 23rd. Zacks Investment Research lowered BioDelivery Sciences International from a “hold” rating to a “sell” rating in a report on Tuesday, October 25th. Piper Jaffray Cos. restated a “sell” rating and issued a $4.00 price objective on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. Cantor Fitzgerald restated a “hold” rating on shares of BioDelivery Sciences International in a report on Wednesday, August 10th. Finally, FBR & Co restated a “buy” rating on shares of BioDelivery Sciences International in a report on Tuesday, September 20th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. BioDelivery Sciences International currently has a consensus rating of “Hold” and a consensus price target of $6.57.

BioDelivery Sciences International (NASDAQ:BDSI) opened at 1.75 on Wednesday. The stock’s market cap is $94.71 million. BioDelivery Sciences International has a 12 month low of $1.50 and a 12 month high of $6.40. The stock has a 50 day moving average price of $2.18 and a 200-day moving average price of $2.38.

In related news, CFO Paolantonio Ernest Robert De sold 14,800 shares of the company’s stock in a transaction on Thursday, September 22nd. The stock was sold at an average price of $2.44, for a total transaction of $36,112.00. Following the transaction, the chief financial officer now directly owns 14,866 shares of the company’s stock, valued at $36,273.04. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Francis E. Odonnell, Jr. sold 100,000 shares of the company’s stock in a transaction on Friday, September 23rd. The shares were sold at an average price of $2.57, for a total value of $257,000.00. The disclosure for this sale can be found here. Corporate insiders own 9.00% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of BDSI. KCG Holdings Inc. raised its position in BioDelivery Sciences International by 235.8% in the third quarter. KCG Holdings Inc. now owns 39,347 shares of the specialty pharmaceutical company’s stock valued at $106,000 after buying an additional 27,630 shares during the last quarter. NEXT Financial Group Inc raised its position in shares of BioDelivery Sciences International by 42.4% in the third quarter. NEXT Financial Group Inc now owns 49,850 shares of the specialty pharmaceutical company’s stock valued at $135,000 after buying an additional 14,850 shares during the last quarter. Janney Montgomery Scott LLC raised its position in shares of BioDelivery Sciences International by 12.0% in the second quarter. Janney Montgomery Scott LLC now owns 61,300 shares of the specialty pharmaceutical company’s stock valued at $294,000 after buying an additional 6,550 shares during the last quarter. Alpine Partners VI LLC purchased a new position in shares of BioDelivery Sciences International during the second quarter valued at $147,000. Finally, Bank of New York Mellon Corp raised its position in shares of BioDelivery Sciences International by 9.9% in the third quarter. Bank of New York Mellon Corp now owns 62,945 shares of the specialty pharmaceutical company’s stock valued at $170,000 after buying an additional 5,677 shares during the last quarter. 60.65% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright law. The correct version of this piece can be read at https://www.thecerbatgem.com/2016/11/24/q2-2017-eps-estimates-for-biodelivery-sciences-international-inc-cut-by-analyst-bdsi.html.

BioDelivery Sciences International Company Profile

BioDelivery Sciences International, Inc is a specialty pharmaceutical company. The Company develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Company develops pharmaceutical products aimed principally in the areas of pain management and addiction.

5 Day Chart for NASDAQ:BDSI

Receive News & Stock Ratings for BioDelivery Sciences International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International Inc. and related stocks with our FREE daily email newsletter.